A Phase 2 interventional study of Neoadjuvant Olaparib monotherapy group and Neoadjuvant combination therapy with olaparib plus durvalumab in Breast Cancer, sponsored by AstraZeneca. Completed at 36 sites in 9 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing olaparib in Breast Neoplasms — 11 open to participants now, 25 under way, 4 of them phase 3. olaparib · Breast Neoplasms.
Among the 51 studies testing olaparib in Breast Neoplasms, this one is the 28th largest by enrollment, is one of 7 that started in 2022, is one of 24 in phase 2, and was the 44th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →11 of the 51 studies testing olaparib in Breast Neoplasms are open now, in 8 countries. Recruiting first, the newest first:
Wen-Ming Cao · Sites in China
Ages 60+ · Women only
Okayama University · Sites in Japan
Ages 18+
Mary D Chamberlin · Sites in United States
Ages 18+ · Women only
German Cancer Research Center · Sites in Germany
Ages 18+
National Taiwan University Hospital · Sites in Taiwan
Ages 20+
By country, each count listing its studies:
olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, olaparib is the treatment under test here. Read study by study →
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 27 · Phase 3 6 · Phase 4 3
First in 2007; this study’s year is marked. 7 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 54 across the 51 interventional studies. Of the 24 that completed or were terminated, 10 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 51 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
198 studies in Breast Neoplasms by AstraZeneca: 20 open now, 50 under way, 24 of them phase 3. Of 144 finished, 32 (22%) have results posted.
Among the 198 studies in Breast Neoplasms by AstraZeneca, this one is the 98th largest by enrollment of the 125 interventional ones that give a count, is one of 10 that started in 2022, is one of 31 in phase 2, and was the 157th registered.
AstraZeneca’s Breast Neoplasms studies by the year they started, since 1996.
4 of the studies testing olaparib in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT03740893Institute of Cancer Research, United KingdomPHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer | 2026-12 |
| NCT03594396Seoul National University HospitalWindow of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer | 2026-12-31 |
| NCT04683679Memorial Sloan Kettering Cancer CenterA Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer | 2027-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 51 studies testing olaparib in Breast Neoplasms, from their registry updates:
Among AstraZeneca’s 198 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study to learn more about olaparib and olaparib plus durvalumab combination therapy and also to better understand the studied disease, breast cancer, and associated health problems.
Olaparib is a type of drug called a PARP (poly [adenosine diphosphate-ribose] polymerase) inhibitor. PARP inhibitors can destroy cancer cells that are not good at repairing DNA damage. Olaparib is also approved by US Food and Drug Administration (FDA), European Medicines Agency (EMA) and in other countries for treating women with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer.
Durvalumab is a type of anticancer drug called immunotherapy that targets cancer cells by blocking the signal that prevents the immune system from seeing the cancer cell. Your immune system can then attack and kill the cancer cells. Durvalumab is approved by the FDA and the EMA for the treatment of patients with locally advanced non-small cell lung cancer after receiving chemoradiation therapy and extensive-stage small cell lung cancer in combination with chemotherapy .
Some parts of this study are experimental, which means that durvalumab and the combination of olaparib and durvalumab are still in the development stage for the treatment of breast cancer, and they are not approved for treatment of breast cancer, except for use in research studies like this.
The investigation of olaparib as monotherapy or olaparib in combination with durvalumab in patients with early stage BRCAm, oestrogen receptor (ER)-negative or ER-low, human epidermal growth factor receptor 2 (HER2)-negative breast cancer who are candidates for neoadjuvant therapy supports the ongoing effort to identify novel agents and new drug combinations that can improve pathological complete response (pCR) rates and event-free survival (EFS). In patients at a lower risk (T1b-c/N0) of disease recurrence and a higher chance for cure, monotherapy olaparib may provide adequate neoadjuvant treatment. In contrast, monotherapy olaparib may be inadequate neoadjuvant treatment for those patients at a higher risk (T2/N0 or T1/N1) of recurrence, and the addition of an immune checkpoint inhibitor (ICI) to the neoadjuvant regimen may improve long-term outcomes as was seen in KEYNOTE-522 and GeparNuevo. However, the risk of irreversible immune-mediated adverse events (AEs) of the endocrine system due to ICI use supports the use of ICIs only in the cohort of patients at higher risk for disease recurrence. For both the lower and higher risk groups, the study treatments have the potential for the development of de-escalation strategies in this disease setting where traditional chemotherapy regimens may be avoided altogether.
While assessment of the efficacy of the combination of olaparib and durvalumab is ongoing, there are sufficient safety data available to develop a safety and tolerability profile for the combination.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
confirmed, newly diagnosed, primary, operable, nonmetastatic invasive breast cancer with the following characteristics:
--ER-negative or ER-low defined as IHC nuclear staining ≤10%
-negative (not eligible for anti-HER2 therapy) defined as:
Clinical TNM staging (per AJCC 8th Edition) as follows:
Exclusion Criteria:
Concomitant use of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort A will consist of a lower-risk population of participants with HER2-negative ER-negative or ER-low defined as having a tumour size \>5 mm and ≤20 mm and N0 (T1b-c/N0).
Drug: Neoadjuvant Olaparib monotherapy group
Cohort B will consist of a higher-risk population of participants with HER2-negative ER-negative or ER-low defined as having a tumour size of \>20 mm but ≤50 mm and N0 (T2/N0), or having a tumour size of \>1 mm but ≤20 mm and N1 (T1/N1).
Combination Product: Neoadjuvant combination therapy with olaparib plus durvalumab
Neoadjuvant olaparib monotherapy (300 mg BID) for four to six 28-day cycles.
Also known as: Cohort A
Drug pages: Olaparib · Durvalumab
Neoadjuvant combination therapy with olaparib (300 mg BID) plus durvalumab (1500 mg IV Q4W) for four to six 28-day cycles.
Also known as: Cohort B
pCR Rate of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination Therapy, Assessed by Central Pathology Review
pCR = pathological complete response pCR was defined as ypT0/Tis ypN0 (ie, no invasive residual in breast and the axillary lymph nodes on evaluation of the complete resected breast specimen and all sampled regional lymph nodes) following completion of neoadjuvant systemic therapy. Results of this outcome measure are from DCO1 (20 November 2024). The Clopper Pearson method is for the computation of the 95% confidence interval (CI).
Time frame: Approx. 4 to 6 months
pCR Rate of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination Therapy, Assessed by Local Pathology Review
pCR was defined as ypT0/Tis ypN0 (ie, no invasive residual in breast and the axillary lymph nodes on evaluation of the complete resected breast specimen and all sampled regional lymph nodes) following completion of neoadjuvant systemic therapy. Results of this outcome measure are from DCO1 (20 November 2024). The Clopper Pearson method is for the computation of the 95% CI.
Time frame: Approx. 4 to 6 months
RCB of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination Therapy as Assessed by Central Pathology Review
RCB = residual cancer burden RCB index value using 6 variables to categorize response in 1 of 4 classes: RCB 0 (pCR), I (minimal RCB), II (moderate RCB), and III (extensive RCB). RCB III included patients who had clinical progression before surgery, and there was no central pCR performed. Results of this outcome measure are from DCO1 (20 November 2024).
Time frame: Approx. 4 to 6 months
RCB of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination Therapy as Assessed by Local Pathology Review
RCB index value using 6 variables to categorize response in 1 of 4 classes: RCB 0 (pCR), I (minimal RCB), II (moderate RCB), and III (extensive RCB). RCB III included patients who had clinical progression before surgery, and there was no central pCR performed. Results of this outcome measure are from DCO1 (20 November 2024).
Time frame: Approx. 4 to 6 months
Percentage Change in Tumour Volume at Week 12 and Week 24 From Baseline
Percentage change in tumour volume at Week 12 and Week 24 from baseline was measured using magnetic resonance imaging (MRI). Baseline was defined as the most recent measurement prior to the first administration of study intervention. Percent change from baseline was defined as: (Difference in value between post-baseline volume and baseline volume) divided by baseline volume and multiplied by 100. Results of this outcome measure are from DCO1 (20 November 2024).
Time frame: Week 12 and Week 24
Number of Participants With EFS (Event-free Survival)
EFS was defined as time from the first dose of study intervention administration to any of the following events: progression of disease that precluded surgery, local or distant recurrence after surgery, second primary malignancy (breast or other invasive cancers), or death due to any cause. Results of this outcome measure are from final DCO (16 September 2025). One of 3 subjects in AZD2281 + MEDI4736 group had a disease progression recorded in error; 2 (8.0%) participants had an EFS event of progression of disease reported in the neoadjuvant period.
Time frame: Approx. 3 years
Number of Participants With AEs
AE = adverse event; ECG = electrocardiogram Data included clinical observations, ECG parameters, haematology/clinical chemistry, vital signs assessed as the number of participants with AEs. Results of participants with AEs are from final DCO (16 September 2025).
Time frame: Through study completion, approximately 34 months
Number of Participants With SAEs
SAE = serious adverse event Data included clinical observations, ECG parameters, haematology/clinical chemistry, vital signs assessed as the number of participants with AEs. Results of participants with SAEs are from final DCO (16 September 2025).
Time frame: Through study completion, approximately 34 months
A total of 114 participants were screened from 28 study sites across 9 countries. Of these, 50 participants were enrolled.
| Milestone | AZD2281 | AZD2281+MEDI4736 |
|---|---|---|
| Started | 25 | 25 |
| Completed | 0 | 0 |
| Not completed | 25 | 25 |
| Withdrew: Site terminated by sponsor | 2 | 2 |
| Withdrew: Study terminated by sponsor | 23 | 22 |
| Withdrew: Withdrawal by subject | 0 | 1 |
pCR = pathological complete response pCR was defined as ypT0/Tis ypN0 (ie, no invasive residual in breast and the axillary lymph nodes on evaluation of the complete resected breast specimen and all sampled regional lymph nodes) following completion of neoadjuvant systemic therapy. Results of this outcome measure are from DCO1 (20 November 2024). The Clopper Pearson method is for the computation of the 95% confidence interval (CI).
| Percentage | AZD2281 | AZD2281+MEDI4736 |
|---|---|---|
| pCR Rate of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination Therapy, Assessed by Central Pathology Review | 68.0 (46.50 to 85.05) | 80.0 (59.30 to 93.17) |
pCR was defined as ypT0/Tis ypN0 (ie, no invasive residual in breast and the axillary lymph nodes on evaluation of the complete resected breast specimen and all sampled regional lymph nodes) following completion of neoadjuvant systemic therapy. Results of this outcome measure are from DCO1 (20 November 2024). The Clopper Pearson method is for the computation of the 95% CI.
| Percentage | AZD2281 | AZD2281+MEDI4736 |
|---|---|---|
| pCR Rate of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination Therapy, Assessed by Local Pathology Review | 68.0 (46.50 to 85.05) | 76.0 (54.87 to 90.64) |
RCB = residual cancer burden RCB index value using 6 variables to categorize response in 1 of 4 classes: RCB 0 (pCR), I (minimal RCB), II (moderate RCB), and III (extensive RCB). RCB III included patients who had clinical progression before surgery, and there was no central pCR performed. Results of this outcome measure are from DCO1 (20 November 2024).
| Participants | AZD2281 | AZD2281+MEDI4736 |
|---|---|---|
| RCB-0 | 17 | 20 |
| RCB-I | 1 | 1 |
| RCB-II | 6 | 1 |
| RCB-III | 1 | 2 |
| Missing | 0 | 1 |
RCB index value using 6 variables to categorize response in 1 of 4 classes: RCB 0 (pCR), I (minimal RCB), II (moderate RCB), and III (extensive RCB). RCB III included patients who had clinical progression before surgery, and there was no central pCR performed. Results of this outcome measure are from DCO1 (20 November 2024).
| Participants | AZD2281 | AZD2281+MEDI4736 |
|---|---|---|
| RCB-0 | 17 | 19 |
| RCB-I | 2 | 2 |
| RCB-II | 5 | 0 |
| RCB-III | 1 | 2 |
| Missing | 0 | 2 |
Percentage change in tumour volume at Week 12 and Week 24 from baseline was measured using magnetic resonance imaging (MRI). Baseline was defined as the most recent measurement prior to the first administration of study intervention. Percent change from baseline was defined as: (Difference in value between post-baseline volume and baseline volume) divided by baseline volume and multiplied by 100. Results of this outcome measure are from DCO1 (20 November 2024).
| Percentage in tumour volume | AZD2281 | AZD2281+MEDI4736 |
|---|---|---|
| Percentage change from baseline at Week 12 | -87.86 ± 17.527 | -84.49 ± 29.998 |
| Percentage change from baseline at Week 24 | -42.32 ± 227.333 | -89.87 ± 34.726 |
EFS was defined as time from the first dose of study intervention administration to any of the following events: progression of disease that precluded surgery, local or distant recurrence after surgery, second primary malignancy (breast or other invasive cancers), or death due to any cause. Results of this outcome measure are from final DCO (16 September 2025). One of 3 subjects in AZD2281 + MEDI4736 group had a disease progression recorded in error; 2 (8.0%) participants had an EFS event of progression of disease reported in the neoadjuvant period.
| Participants | AZD2281 | AZD2281+MEDI4736 |
|---|---|---|
| Number of Participants With EFS (Event-free Survival) | 3 | 3 |
AE = adverse event; ECG = electrocardiogram Data included clinical observations, ECG parameters, haematology/clinical chemistry, vital signs assessed as the number of participants with AEs. Results of participants with AEs are from final DCO (16 September 2025).
| Participants | AZD2281 | AZD2281+MEDI4736 |
|---|---|---|
| Number of Participants With AEs | 24 | 24 |
SAE = serious adverse event Data included clinical observations, ECG parameters, haematology/clinical chemistry, vital signs assessed as the number of participants with AEs. Results of participants with SAEs are from final DCO (16 September 2025).
| Participants | AZD2281 | AZD2281+MEDI4736 |
|---|---|---|
| Number of Participants With SAEs | 4 | 5 |
Collected over AEs were collected from the time of informed consent form signature through study completion, approximately 34 months (final DCO: 16 September 2025).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AZD2281 | 0/25 (0%) | 4/25 (16%) | 23/25 (92%) |
| AZD2281+MEDI4736 | 0/25 (0%) | 5/25 (20%) | 23/25 (92%) |
| Event | AZD2281 | AZD2281+MEDI4736 |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 2/25 | 0/25 |
| Pelvic massGeneral disorders | 1/25 | 0/25 |
| HypersensitivityImmune system disorders | 0/25 | 1/25 |
| BronchitisInfections and infestations | 0/25 | 1/25 |
| Post procedural infectionInfections and infestations | 0/25 | 1/25 |
| Alanine aminotransferase increasedInvestigations | 0/25 | 1/25 |
| Aspartate aminotransferase increasedInvestigations | 0/25 | 1/25 |
| Diabetes mellitusMetabolism and nutrition disorders | 0/25 | 1/25 |
| Transient ischaemic attackNervous system disorders | 0/25 | 1/25 |
| Internal device exposedProduct Issues | 1/25 | 1/25 |
| Event | AZD2281 | AZD2281+MEDI4736 |
|---|---|---|
| NauseaGastrointestinal disorders | 15/25 | 19/25 |
| FatigueGeneral disorders | 9/25 | 13/25 |
| DiarrhoeaGastrointestinal disorders | 10/25 | 9/25 |
| AstheniaGeneral disorders | 10/25 | 8/25 |
| AnaemiaBlood and lymphatic system disorders | 10/25 | 9/25 |
| DysgeusiaNervous system disorders | 8/25 | 4/25 |
| HeadacheNervous system disorders | 8/25 | 8/25 |
| HypothyroidismEndocrine disorders | 0/25 | 7/25 |
| VomitingGastrointestinal disorders | 3/25 | 5/25 |
| PyrexiaGeneral disorders | 2/25 | 5/25 |
Full Analysis Set: Included all enrolled participants who received at least 1 dose of study intervention.
| Age, Continuous(Years) | AZD2281 | AZD2281+MEDI4736 | Total |
|---|---|---|---|
| Mean | 47.8 ± 10.32 | 47.2 ± 14.24 | 47.5 ± 12.31 |
| Age, Customized(Participants) | AZD2281 | AZD2281+MEDI4736 | Total |
|---|---|---|---|
| < 30 | 0 | 1 | 1 |
| 30 - 39 | 6 | 8 | 14 |
| 40 - 49 | 11 | 8 | 19 |
| 50 - 59 | 3 | 3 | 6 |
| 60 - 69 | 5 | 3 | 8 |
| >= 70 | 0 | 2 | 2 |
| Sex: Female, Male(Participants) | AZD2281 | AZD2281+MEDI4736 | Total |
|---|---|---|---|
| Female | 25 | 25 | 50 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | AZD2281 | AZD2281+MEDI4736 | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 2 |
| Not Hispanic or Latino | 23 | 25 | 48 |
| Race/Ethnicity, Customized(Participants) | AZD2281 | AZD2281+MEDI4736 | Total |
|---|---|---|---|
| Black or African American | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| White | 24 | 20 | 44 |
| Other | 0 | 3 | 3 |
| Not reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | AZD2281 | AZD2281+MEDI4736 | Total |
|---|---|---|---|
| Spain | 13 | 9 | 22 |
| Germany | 5 | 5 | 10 |
| United States | 2 | 2 | 4 |
| Australia | 1 | 2 | 3 |
| Belgium | 1 | 2 | 3 |
| Italy | 1 | 2 | 3 |
| Austria | 1 | 1 | 2 |
| Israel | 1 | 1 | 2 |
| United Kingdom | 0 | 1 | 1 |
| Height(cm) | AZD2281 | AZD2281+MEDI4736 | Total |
|---|---|---|---|
| Mean | 162.3 ± 6.55 | 162.3 ± 6.67 | 162.3 ± 6.54 |
| Weight(kg) | AZD2281 | AZD2281+MEDI4736 | Total |
|---|---|---|---|
| Mean | 68.29 ± 15.767 | 69.38 ± 12.380 | 68.83 ± 14.040 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2022 to primary completion in Nov 2024, 24 months.
Results were first posted in Sep 2026, 1 year 10 months after primary completion. A results delay was requested in Aug 2025.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 24 months is below that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Sep 2025, on Sep 25, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Olaparib · Durvalumab